In this interview, NewsMedical speaks with Jeff Hawkins, CEO of Quantum-Si, about the challenges of conventional proteomic methods, as well as how next-generation protein sequencing is democratizing protein sequencing.
Takeda says TYK2 drug it purchased for $4B has passed another mid-stage test
Takeda announced Monday morning that the TYK2 inhibitor it bought from Nimbus Therapeutics for $4 billion has succeeded in a Phase IIb trial in psoriatic